2.50
0.40%
+0.010
After Hours:
2.50
Stereotaxis Inc stock is currently priced at $2.50, with a 24-hour trading volume of 176.71K.
It has seen a +0.40% increased in the last 24 hours and a -0.40% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.49 pivot point. If it approaches the $2.54 resistance level, significant changes may occur.
Stereotaxis Inc Stock (STXS) Financials Data
Stereotaxis Inc (STXS) Revenue 2024
STXS reported a revenue (TTM) of $26.77 million for the quarter ending December 31, 2023, a -4.89% decline year-over-year.
Stereotaxis Inc (STXS) Net Income 2024
STXS net income (TTM) was -$20.71 million for the quarter ending December 31, 2023, a -13.24% decrease year-over-year.
Stereotaxis Inc (STXS) Cash Flow 2024
STXS recorded a free cash flow (TTM) of -$9.51 million for the quarter ending December 31, 2023, a +11.93% increase year-over-year.
Stereotaxis Inc (STXS) Earnings per Share 2024
STXS earnings per share (TTM) was -$0.27 for the quarter ending December 31, 2023, a -3.85% decline year-over-year.
Stereotaxis Inc Stock (STXS) Latest News
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
GlobeNewswire Inc.
Major Regulatory Approvals Coming For Stereotaxis In The Next 10 Months
Seeking Alpha
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Zacks Investment Research
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States
GlobeNewswire Inc.
Stereotaxis Reports 2023 Full Year Financial Results
GlobeNewswire Inc.
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
About Stereotaxis Inc
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
Cap:
|
Volume (24h):